Cisplatin: mode of cytotoxic action and molecular basis of resistance
The DOI matches its Crossref record; 156 of the 156 references it cites were found in a registry or an index.
Abstract
Cisplatin is one of the most potent antitumor agents known, displaying clinical activity against a wide variety of solid tumors. Its cytotoxic mode of action is mediated by its interaction with DNA to form DNA adducts, primarily intrastrand crosslink adducts, which activate several signal transduction pathways, including those involving ATR, p53, p73, and MAPK, and culminate in the activation of apoptosis. DNA damage-mediated apoptotic signals, however, can be attenuated, and the resistance that ensues is a major limitation of cisplatin-based chemotherapy. The mechanisms responsible for cisplatin resistance are several, and contribute to the multifactorial nature of the problem. Resistance mechanisms that limit the extent of DNA damage include reduced drug uptake, increased drug inactivation, and increased DNA adduct repair. Origins of these pharmacologic-based mechanisms, however, are at the molecular level. Mechanisms that inhibit propagation of the DNA damage signal to the apoptotic machinery include loss of damage recognition, overexpression of HER-2/neu, activation of the PI3-K/Akt (also known as PI3-K/PKB) pathway, loss of p53 function, overexpression of antiapoptotic bcl-2, and interference in caspase activation. The molecular signature defining the resistant phenotype varies between tumors, and the number of resistance mechanisms activated in response to selection pressures dictates the overall extent of cisplatin resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ATM kinase seems to be activated primarily in response to the induction of double-strand breaks whereas ATR is critical for cellular checkpoint responses to stalled replication forks and to many types of DNA damage, such as those induced by UV light and cisplatin (16,17).”
In the citing paper
“Clinical use of cisplatin is complicated by the dose-limiting side effects as well as rapid development of drug resistance [5].”
Citations
Cites
1 retracted
BRCA1 required for transcription-coupled repair of oxidative DNA damage
Gowen, L. C., Avrutskaya, A. V., Latour, A. M., Koller, B. H., & Leadon, S. A. (1998) · Science · doi:10.1126/science.281.5379.1009 · Cited by 496
RetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018 · cited 1×
“A major factor affecting the loss of apoptotic function is p53 gene mutation (see Figure 6), which is observed in about a half of all cancers (Hollstein et al., 1991; Soussi, 2000).”
BackgroundStudies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Bcl-2 functions in an antioxidant pathway to prevent apoptosis
Hockenbery, D. M., Oltvai, Z. N., Yin, X.-M., Milliman, C. L., & Korsmeyer, S. J. (1993) · Cell · doi:10.1016/0092-8674(93)80066-n · Cited by 3,419
Hartwell, L. H., & Kastan, M. B. (1994) · Science · doi:10.1126/science.7997877 · Cited by 2,535
Regulation of Cell Death Protease Caspase-9 by Phosphorylation
Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., & Reed, J. C. (1998) · Science · doi:10.1126/science.282.5392.1318 · Cited by 2,481
Mitogen-activated protein kinase pathways
Robinson, M. J., & Cobb, M. H. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80061-0 · Cited by 2,474
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100 · cited 2×
“Intracellular factors that may inhibit such an activation of p53 include overexpression of the negative feedback regulator Mdm2 and downregulation of the moderator of Mdm2, p14ARF (Fritsche et al., 1993; Shieh et al., 1997; Lakin and Jackson, 1999; Meek, 1999; Deng et al., 2002).”
BackgroundA family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751 · cited 1×
“…resistance-associated (MRP) gene family, composed of at least seven members (MRP1–7), has been a major target of investigations, primarily as several of these ABC membrane proteins have been found in tumor cells and associated with cellular efflux of a variety of drugs (Borst et al., 2000).”
Background
Research works printed but not linked: 5
- Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ and Kaufmann SH. (1997). Blood, 90, 935–943. · doi:10.1182/blood.v90.3.935.935_935_943 · Paper page
- Eisenhauer E, Swerton K, Sturgeon J, Fine S, O'Reilly S and Canetta R . (1990). Carboplatin: Current Perspectives and Future Directions. Bunn P, Canetta R, Ozols R and Rozencweig M (eds). WB Saunders Company: Philadelphia, PA, pp. 133–140.
- He G and Siddik ZH . (2001). Proc. Am. Assoc. Cancer Res., 42, 901.
- Holford J, Rogers P and Kelland LR . (1998). Int. J. Cancer, 77, 94–100. · doi:10.1002/(sici)1097-0215(19980703)77:1<94::aid-ijc15>3.0.co;2-9
- Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El Naggar A, Minguillon C, Schonborn I, Reich O, Kreienberg R, Lichtenegger W and Press MF . (2001). Clin. Cancer Res., 7, 2984–2997.
Cited by
Items 701–800 of 1,004
Mendoza‐Pérez, J., Martínez, J. G., Hernández, C. H., Pérez‐Montiel, D., Castro, C., Fabián-Morales, E., Santibáñez-Andrade, M., González‐Barrios, R., Díaz‐Chávez, J., Andonegui, M. A., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.303 · Cited by 57
Du, B., Dai, X., Li, S., Qi, G., Cao, G., Zhong, Y., Yin, P., & Yang, X. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.377 · Cited by 65
“at themoment simply because its replacements have not been as effective.(19) Thus, it will be necessary to explore novel strategies to minimize cisplatin-induced nephrotoxicity.”
Harris, A. L., Ryan, J. J., & Farrell, N. P. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.018762 · Cited by 58
Antitumor Activity of Pt(II), Ru(III) and Cu(II) Complexes
Gałczyńska, K., Drulis‐Kawa, Z., & Arabski, M. (2020) · Molecules · doi:10.3390/molecules25153492 · Cited by 61
Červinka, J., Gobbo, A., Biancalana, L., Marková, L., Novohradský, V., Guelfi, M., Zacchini, S., Kašpárková, J., Brabec, V., & Marchetti, F. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00722 · Cited by 61
Roy, N., & Paira, P. (2024) · ACS Omega · doi:10.1021/acsomega.3c08890 · Cited by 63
“18 − 20 Hence, successful cancer therapy encounters great challenges.”
BackgroundKesavan, A., Ilaiyaraja, P., Beaula, W. S., Kumari, V. V., Sugin Lal Jabaris, S., Arunkumar, C., Anjana, G., Kondaveeti, S. S., Ramesh, A., Rayala, S. K., et al. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.08.001 · Cited by 57
Liang, X., Shen, D., Chen, K. G., Wincovitch, S., Garfield, S. H., & Gottesman, M. M. (2004) · Journal of Cellular Physiology · doi:10.1002/jcp.20253 · Cited by 57
Mitochondrial Proteomic Analysis of Cisplatin Resistance in Ovarian Cancer
Chappell, N. P., Teng, P.-N., Hood, B. L., Wang, G., Darcy, K. M., Hamilton, C. A., Maxwell, G. L., & Conrads, T. P. (2012) · Journal of Proteome Research · doi:10.1021/pr300403d · Cited by 63
Almeida, G. M., Duarte, T. L., Farmer, P. B., Steward, W. P., & Jones, G. D. D. (2007) · International Journal of Cancer · doi:10.1002/ijc.23188 · Cited by 60
MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines
Kumar, S. R., Kumar, A. R., Shah, P. P., Rai, S. N., Panguluri, S. K., & Kakar, S. S. (2011) · Journal of Ovarian Research · doi:10.1186/1757-2215-4-17 · Cited by 58
Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer
Koster, R., van Vugt, M. A. T. M., Timmer‐Bosscha, H., Gietema, J. A., & de Jong, S. (2013) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2013.13 · Cited by 66
Ecotoxicological assessment of the anticancer drug cisplatin in the polychaete Nereis diversicolor
da Fonseca, T. G., Morais, M., Rocha, T. L., Abessa, D. M. D. S., Aureliano, M., & Bebianno, M. J. (2016) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2016.09.185 · Cited by 63
TMEM16A/ANO1 Inhibits Apoptosis Via Downregulation of Bim Expression
Godse, N. R., Khan, N. I., Yochum, Z. A., Gomez-Casal, R., Kemp, C., Shiwarski, D. J., Seethala, R. S., Kulich, S. M., Seshadri, M., Burns, T. F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1561 · Cited by 57
“Multiple mechanisms of resistance have been proposed, including reduced intracellular accumulation of drug, drug inactivation, and alterations in DNA damage-sensing mechanisms (22).”
BackgroundAdusumilli, P. S., Chan, M.-K., Chun, Y. S., Hezel, M. P., Chou, T., Rusch, V. W., & Fong, Y. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.1.2237 · Cited by 61
Granada, A. E., Jiménez, A., Stewart-Ornstein, J., Blüthgen, N., Reber, S., Jambhekar, A., & Lahav, G. (2020) · Molecular Biology of the Cell · doi:10.1091/mbc.e19-09-0515 · Cited by 67
“Indeed, the DNA-damaging agent cisplatin is known to halt proliferation by inducing both cell death and cell cycle arrest (Siddik, 2003; Galluzzi et al., 2012; Paek et al., 2016; Martins et al., 2018).”
BackgroundMolecular mechanisms associated with chemoresistance in esophageal cancer
Lohan-Codeço, M., Barambo-Wagner, M. L., Nasciutti, L. E., Pinto, L. F. R., Costa, N. M. D., & Palumbo, A. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04131-6 · Cited by 67
Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy
Vianello, C., Cocetta, V., Catanzaro, D., Dorn, G. W., Milito, A. D., Rizzolio, F., Canzonieri, V., Cecchin, E., Roncato, R., Toffoli, G., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04741-9 · Cited by 66
“Indeed, apoptosis reduction has been proposed as a key mechanism in the resistance process [34].”
BackgroundEpigenetic considerations for endometrial cancer prevention, diagnosis and treatment
ZHOU, X., Dowdy, S. C., Podratz, K. C., & JIANG, S. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.06.019 · Cited by 56
Involvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in ovarian cancer cells
Wang, J., Zhou, J., Zhang, L., & Wu, G. S. (2009) · Cell Cycle · doi:10.4161/cc.8.19.9751 · Cited by 58
Pyrophosphate-bridged complexes with picomolar toxicity
Ikotun, O. F., Higbee-Dempsey, E. M., Ouellette, W., & Doyle, R. P. (2009) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2009.07.010 · Cited by 57
Cisplatin Resistant Spheroids Model Clinically Relevant Survival Mechanisms in Ovarian Tumors
Chowanadisai, W., Messerli, S. M., Miller, D. H., Medina, J. E., Hamilton, J. W., Messerli, M. A., & Brodsky, A. S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151089 · Cited by 67
Pharmacologic and Chemical Adjuvants in Tumor Virotherapy
Alvarez-Breckenridge, C. A., Kaur, B., & Chiocca, E. A. (2009) · Chemical Reviews · doi:10.1021/cr900048k · Cited by 62
Ma, Y., Yu, W., Hershberger, P. A., Flynn, G., Kong, R.-X., Trump, D. L., & Johnson, C. S. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0243 · Cited by 61
Toll-like receptor 4 is activated by platinum and contributes to cisplatin-induced ototoxicity
Babolmorad, G., Latif, A., Pollock, N. M., Domingo, I. K., Delyea, C., Rieger, A. M., Allison, W. T., & Bhavsar, A. P. (2021) · EMBO Reports · doi:10.15252/embr.202051280 · Cited by 60
“The anti-tumor activity of cisplatin is based on its formation of intra-strand and inter-strand guanine crosslinks in DNA that prevent the strands from separating, or it alkylates DNA bases causing DNA miscoding (Siddik, 2003).”
MicroRNAs as the critical regulators of Cisplatin resistance in ovarian cancer cells
Moghbeli, M. (2021) · Journal of Ovarian Research · doi:10.1186/s13048-021-00882-1 · Cited by 62
“DDP resistance in OC is associated with abnormal drug transportation, increased detoxification, abnormal apoptosis, and abnormal DNA repair ability [15, 16].”
BackgroundWheeler, H. E., Gamazon, E. R., Stark, A. L., O’Donnell, P. H., Gorsic, L. K., Huang, R. S., Cox, N. J., & Dolan, M. E. (2011) · The Pharmacogenomics Journal · doi:10.1038/tpj.2011.38 · Cited by 63
Proetto, M. T., Liu, W., Hagenbach, A., Abram, U., & Gust, R. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.03.053 · Cited by 55
Recombinant human PDCD5 sensitizes chondrosarcomas to cisplatin chemotherapy in vitro and in vivo
Chen, C., Zhou, H., Xu, L., Xu, D. M., Wang, Y., Zhang, Y., Liu, X., Liu, Z., Ma, D., Ma, Q., et al. (2010) · APOPTOSIS · doi:10.1007/s10495-010-0489-5 · Cited by 55
Chen, X., Wu, J., Lai, Y.-W., Zhao, R. Y., Chao, H., & Ji, L. (2013) · Dalton Transactions · doi:10.1039/c3dt32921f · Cited by 56
Yu, K.-H., Levine, D. A., Zhang, H., Chan, D. W., Zhang, Z., & Snyder, M. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b01129 · Cited by 55
Pharmacogenetics of Drug-Induced Ototoxicity Caused by Aminoglycosides and Cisplatin
Lanvers‐Kaminsky, C., & Ciarimboli, G. (2017) · Pharmacogenomics · doi:10.2217/pgs-2017-0125 · Cited by 62
“Binding of platin to DNA blocks DNA replication and transcription, induces DNA repair and cell cycle arrest and is responsible for the cytotoxicity of cisplatin against proliferating tumor cells [24,25].”
BackgroundPlatinum iodido complexes: A comprehensive overview of anticancer activity and mechanisms of action
Štarha, P., Vančo, J., & Trávníček, Z. (2018) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2018.09.017 · Cited by 56
Allen, C. M., Lopes, F., Mitchell, R. T., & Spears, N. (2020) · Molecular Human Reproduction · doi:10.1093/molehr/gaaa008 · Cited by 58
“…to the formation of DNA adducts, resulting in cross-linkage and subsequent DNA damage: whether there is any underlying mechanism that may account for the observed differences in toxicity prolife of these two drugs is, however, not yet clear (reviewed in Siddik, 2003; Dasari and Tchounwou, 2014).”
BackgroundLiao, X., Gao, Y., Zhao, H., Zhou, M., Chen, D., Tao, L.-T., Guo, W., Sun, L., Gu, C., Chen, H., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.609285 · Cited by 57
“%) histological subtype of the disease (Siegel et al., 2019).”
Biancalana, L., Franco, M. D., Ciancaleoni, G., Zacchini, S., Pampaloni, G., Gandin, V., & Marchetti, F. (2021) · Chemistry - A European Journal · doi:10.1002/chem.202101048 · Cited by 60
Yu, L., Guo, Y., Chang, Z., Zhang, D., Zhang, S., Pei, H., Pang, J., Zhao, Z. J., & Chen, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.764119 · Cited by 61
Ramu, V., Gill, M. R., Jarman, P. J., Turton, D., Thomas, J. A., Das, A., & Smythe, C. (2015) · Chemistry - A European Journal · doi:10.1002/chem.201500561 · Cited by 59
LaPensee, E. W., LaPensee, C. R., Fox, S. R., Schwemberger, S. J., Afton, S. E., & Ben‐Jonathan, N. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.09.005 · Cited by 58
Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer
Comen, E. A., & Robson, M. E. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181cf01eb · Cited by 61
Kašpárková, J., Suchánková, T., Halámiková, A., Zerzánková, L., Vrána, O., Margiotta, N., Natile, G., & Brabec, V. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.09.019 · Cited by 54
Deshpande, N. U., & Jayakannan, M. (2016) · Biomacromolecules · doi:10.1021/acs.biomac.6b01411 · Cited by 54
“Heat shock protein 70 in pancreatic diseases: Friend or foe”
Giri, B., Sethi, V., Modi, S., Garg, B., Banerjee, S., Saluja, A. K., & Dudeja, V. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24653 · Cited by 58
“repair (NER) pathway which excises and repairs these crosslinks.(79)We found that Minnelide treatment of pancreatic cancer cells suppressed Nucleotide Exchange Repair (NER) pathway via a decrease in AP-1 promoter activity.”
BackgroundClemens, E., de Vries, A. C., Zehnhoff‐Dinnesen, A. A., Tissing, W. J. E., Loonen, J. J., Pluijm, S. F. M., Broeder, E. V. D., Bresters, D., Versluys, B. A. B., Kremer, L. C. M., et al. (2017) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2017.1323985 · Cited by 57
“In vitro, this results in the activation of apoptosis [17].”
Lai, Y.-H., Kuo, C., Kuo, M. T., & Chen, H. H. W. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051486 · Cited by 55
“Mechanisms of cDDP resistance are complex, and defective drug transport is commonly associated with cDDP resistance [63,118,119].”
BackgroundWu, Y.-Y., Wu, H., Wu, J.-E., Huang, K., Yang, S., Chen, S.-X., Tsao, C.-J., Hsu, K., Chen, Y., & Hong, T.-M. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1282-0 · Cited by 65
Vandghanooni, S., Eskandani, M., Barar, J., & Omidi, Y. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118729 · Cited by 59
Saeed, H. K., Sreedharan, S., Jarman, P. J., Archer, S. A., Fairbanks, S. D., Foxon, S. P., Auty, A. J., Chekulaev, D., Keane, T., Meijer, A. J. H. M., et al. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b12564 · Cited by 54
Clinical Pathology, Immunopathology and Advanced Vaccine Technology in Bovine Theileriosis: A Review
Agina, O. A., Shaari, M. R., Isa, N. M. M., Ajat, M., Saad, M. Z., & Hamzah, H. B. (2020) · Pathogens · doi:10.3390/pathogens9090697 · Cited by 75
Photoactivated Nanosheets Accelerate Nucleus Access of Cisplatin for Drug‐Resistant Cancer Therapy
Gao, F., Yang, X. F., Luo, X., Xue, X., Qian, C., & Sun, M. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202001546 · Cited by 56
Wang, S. J., & Bourguignon, L. (2006) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.132.1.19 · Cited by 54
Villedieu, M., Deslandes, E., Duval, M., Héron, J., Gauduchon, P., & Poulain, L. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.11.017 · Cited by 56
Bannon, J. H., Fichtner, I., O'Neill, A., Pampillón, C., Sweeney, N. J., Strohfeldt, K. A., Watson, R. W. G., Tacke, M., & Gee, M. M. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604021 · Cited by 54
Shostak, K., Jiang, Z., Charloteaux, B., Mayer, A., Habraken, Y., Tharun, L., Klein, S., Xu, X., Duong, H. Q., Vislovukh, A. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15003-7 · Cited by 57
Kim, J. H., Ofori, S., Parkin, S., Vekaria, H. J., Sullivan, P. G., & Awuah, S. G. (2021) · Chemical Science · doi:10.1039/d1sc01418h · Cited by 59
Guo, Z., Xu, W., Xu, G., & Jia, Q. (2023) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2023.117275 · Cited by 52
cis-Pt I 2 (NH 3 ) 2 : a reappraisal
Marzo, T., Pillozzi, S., Hrabina, O., Kašpárková, J., Brabec, V., Arcangeli, A., Bartoli, G., Severi, M., Lunghi, A., Totti, F., et al. (2015) · Dalton Transactions · doi:10.1039/c5dt01196e · Cited by 54
Ko, J., Su, Y.-J., Lin, S.-T., Jhan, J.-Y., Ciou, S., Cheng, C., Chiu, Y., Kuo, Y., Tsai, M., & Lin, Y. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.10.013 · Cited by 56
Huang, G., Mills, L., & Worth, L. L. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0580 · Cited by 62
Predicting idiopathic toxicity of cisplatin by a pharmacometabonomic approach
Kwon, H. N., Kim, M. K., Wen, H., Kang, S., Yang, H.-J., Choi, M.-J., Lee, H. S., Choi, D., Park, I. S., Suh, Y. J., et al. (2010) · Kidney International · doi:10.1038/ki.2010.440 · Cited by 54
Marı́n, J. J. G., Monte, M. J., Blazquez, A. G., Macı́as, R. I. R., Serrano, M. A., & Briz, Ó. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.131 · Cited by 53
Interleukin-6 modulates oxidative stress produced during the development of cisplatin nephrotoxicity
Mitazaki, S., Hashimoto, M., Matsuhashi, Y., Honma, S., Suto, M., Kato, N., Nakagawasai, O., Tan–No, K., Hiraiwa, K., Yoshida, M., et al. (2013) · Life Sciences · doi:10.1016/j.lfs.2013.01.026 · Cited by 53
Germani, A., Matrone, A., Grossi, V., Peserico, A., Sanese, P., Liuzzi, M., Palermo, R., Murzilli, S., Campese, A. F., Ingravallo, G., et al. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.10.035 · Cited by 55
“It is known that cisplatin induces a wide range of signaling pathways that lead to apoptotic cell death in cancer cells [29].”
BackgroundPickard, A. J., Liu, F., Bartenstein, T. F., Haines, L. G., Levine, K. E., Kucera, G. L., & Bierbach, U. (2014) · Chemistry - A European Journal · doi:10.1002/chem.201404845 · Cited by 53
Muscolini, M., Cianfrocca, R., Sajeva, A., Mozzetti, S., Ferrandina, G., Costanzo, A., & Tuosto, L. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0299 · Cited by 56
Dmitriev, O. Y. (2011) · Biochemistry and Cell Biology · doi:10.1139/o10-150 · Cited by 58
Burkitt, K., & Ljungman, M. E. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-24 · Cited by 58
MicroRNAs as Regulators of Cisplatin Resistance in Lung Cancer
Chen, Y., Gao, Y., Zhang, K., Li, C., Pan, Y., Chen, J., Wang, R., & Chen, L. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000438548 · Cited by 54
Jiang, W., Yan, Y., Chen, M., Luo, G., Hao, J., Pan, J., Hu, S. C., Guo, P., Li, W., Wang, R., et al. (2020) · Aging · doi:10.18632/aging.102644 · Cited by 55
“generation of DNA lesions and the induction of mitochondrial apoptosis via forming DNA adducts with platinum atoms [7].”
BackgroundFojo, T., Farrell, N., Ortuzar, W. I., Tanimura, H., Weinstein, J. N., & Myers, T. G. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.09.008 · Cited by 53
Chen, R., Liu, C., Zhang, H., Guo, Y., Bu, X., & Yang, M. (2006) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2006.11.001 · Cited by 53
Molecular changes to HeLa cells on continuous exposure to cisplatin or paclitaxel
Takara, K., Obata, Y., Yoshikawa, E., Kitada, N., Sakaeda, T., Ohnishi, N., & Yokoyama, T. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0226-5 · Cited by 53
Sail, V., Rizzo, A. A., Chatterjee, N., Dash, R. C., Ozen, Z., Walker, G. C., Korzhnev, D. M., & Hadden, M. K. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.6b01144 · Cited by 52
Oh, S. J., Lim, J. Y., Son, M. K., Ahn, J. H., Song, K., Lee, H., Kim, S., Cho, E., Chung, J., Cho, H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38318-7 · Cited by 61
Oliveira, C. A., Mercês, É. A. B., Portela, F. S., Malheiro, L. F. L., Silva, H. B. L., Benedictis, L. M. D., Benedictis, J. M. D., Silva, C. C. D. E., Santos, A. C. L., Rosa, D. P., et al. (2024) · Clinical and Experimental Nephrology · doi:10.1007/s10157-024-02490-x · Cited by 65
Cheong, S. C., Wang, Y., Meng, J.-H., Hill, R., Sweeney, K. G., Kirn, D. H., Lemoine, N. R., & Halldén, G. (2007) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701099 · Cited by 53
Capsaicin Ameliorates Cisplatin-Induced Renal Injury through Induction of Heme Oxygenase-1
Jung, S.-H., Kim, H., Oh, G., Shen, A., Lee, S., Choe, S., Park, R., & So, H. (2014) · Molecules and Cells · doi:10.14348/molcells.2014.2322 · Cited by 53
“In particular, nephrotoxicity induced by cisplatin is closely associated with oxidative stress and inflammation.”
BackgroundLin, H., Shi, M., Tseng, H., & Chen, J. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kfu032 · Cited by 57
“The formation of platinum-DNA adducts that activate several signal transduction pathways and the ultimate activation of apoptosis contributed to the major cytotoxic effect of CDDP (Reed, 1999; Siddik, 2003).”
BackgroundWang, J., Pabla, N., Wang, C., Wang, W., Schoenlein, P. V., & Dong, Z. (2006) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00509.2005 · Cited by 60
Rébillard, A., Jouan-Lanhouet, S., Jouan, E., Legembre, P., Pizon, M., Sergent, O., Gilot, D., Tekpli, X., Lagadic‐Gossmann, D., & Dimanche‐Boitrel, M. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.01.034 · Cited by 59
Aird, K. M., Li, H., Xin, F., Konstantinopoulos, P. A., & Zhang, R. (2013) · Cell Cycle · doi:10.4161/cc.26953 · Cited by 59
“Cisplatin, which is the primary front-line chemotherapy used for EOC,(5) also induces DNA damage.(43) Therefore, it is interesting to speculate whether there might be synergism between RRM2 inhibition and cisplatin treatment to increase the DNA damage to a threshold beyond which senescence would occur.”
BackgroundFerroni, P., Della‐Morte, D., Palmirotta, R., McClendon, M. S., Testa, G., Abete, P., Rengo, F., Rundek, T., Guadagni, F., & Roselli, M. (2011) · Rejuvenation Research · doi:10.1089/rej.2010.1141 · Cited by 56
Cytotoxicity of a Ti(IV) compound is independent of serum proteins
Tinoco, A. D., Thomas, H. R., Incarvito, C. D., Saghatelian, A., & Valentine, A. M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119303109 · Cited by 52
Overexpression ofβ-Catenin Induces Cisplatin Resistance in Oral Squamous Cell Carcinoma
Li, L., Liu, H.-C., Wang, C., Liu, X., Hu, F.-C., Xie, N., Lü, L., Chen, X., & Huang, H.-Z. (2016) · BioMed Research International · doi:10.1155/2016/5378567 · Cited by 66
“Accumulation of nuclear 𝛽-catenin and the subsequent binding to Tcf transcription factors [36] promoted the overexpression of downstream target genes, such as C-myc, which we also observed in our results.”
BackgroundInfluentialBaicalin attenuates DDP (cisplatin) resistance in lung cancer by downregulating MARK2 and p-Akt
Xu, Z., Mei, J., & Tan, Y. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3768 · Cited by 54
Pauzi, A. Z. M., Yeap, S. K., Abu, N., Lim, K. L., Omar, A. R., Aziz, S. A., Chow, A. L. T., Subramani, T., Tan, S. G., & Alitheen, N. B. (2016) · Chinese Medicine · doi:10.1186/s13020-016-0118-5 · Cited by 64
“Cisplatin exerts its activity through the formation of intra- and inter-strand DNA adducts that damage the DNA and interferes with its normal functions [6, 26].”
BackgroundAwuah, S. G., Riddell, I. A., & Lippard, S. J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1615327114 · Cited by 56
“The well-studied antitumor activity of cisplatin involves binding to DNA, inhibition of transcription, and induction of apoptosis (7, 8).”
BackgroundCancer‐Specific, Intracellular, Reductive Activation of Anticancer PtIV Prodrugs
Reshetnikov, V., Daum, S., & Mokhir, A. A. (2017) · Chemistry - A European Journal · doi:10.1002/chem.201701192 · Cited by 53
Harper, B. W. J., Petruzzella, E., Sirota, R., Faccioli, F. F., Aldrich-Wright, J. R., Gandin, V., & Gibson, D. (2017) · Dalton Transactions · doi:10.1039/c7dt01054k · Cited by 52
de Carvalho, N. C., Neves, S. P., Dias, R. B., Valverde, L. D. F., Sales, C. B. S., Rocha, C. A. G., Soares, M. B. P., dos Santos, E. R., Oliveira, R. M. M., Carlos, R. M., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0104-6 · Cited by 56
Ngo, L. P., Owiti, N. A., Swartz, C. D., Winters, J., Su, Y., Ge, J., Xiong, A., Han, J., Recio, L., Samson, L. D., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz1077 · Cited by 55
c-MYC and Epithelial Ovarian Cancer
Reyes‐González, J. M., & Vivas‐Mejía, P. E. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.601512 · Cited by 65
“Several mechanisms of platinum resistance have been proposed, including the altered expression of oncogenes such as c-MYC (4, 5).”
BackgroundServidei, T., Riccardi, A., Sanguinetti, M., Dominici, C., & Riccardi, R. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20659 · Cited by 52
Solár, P., & Sytkowski, A. J. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.05.008 · Cited by 52
Prewett, M., Deevi, D. S., Bassi, R., Fan, F., Ellis, L. M., Hicklin, D. J., & Tonra, J. R. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1768 · Cited by 52
Role of the transcription factor Ets-1 in cisplatin resistance
Wilson, A., Yamamoto, H., & Singh, G. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.823.3.7 · Cited by 52
Revisiting Platinum-Based Anticancer Drugs to Overcome Gliomas
Jeon, J., Lee, S.-M., Kim, H., Kang, H., Youn, H., Jo, S., Youn, B., & Kim, H. Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105111 · Cited by 54
“It has been shown that the activation of phosphorylated GSTP1, which catalyzes the conjugation of cisplatin and glutathione, correlated significantly with increased glutathionyl-platinum formation, decreased DNA strand crosslink formation, and increased cisplatin resistance [123,124].”
BackgroundBiologic Activity of a Dinuclear Pd(II)–Spermine Complex Toward Human Breast Cancer
Fiuza, S. M., Holy, J. M., de Carvalho, L. A. E. B., & Marques, M. P. M. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2011.01081.x · Cited by 59
The Role of the COP9 Signalosome and Neddylation in DNA Damage Signaling and Repair
Chung, D., & Dellaire, G. (2015) · Biomolecules · doi:10.3390/biom5042388 · Cited by 53
“However, some tumors adapt to DNA damage-inducing chemotherapeutic drugs, such as cisplatin, by enhancing DDR activity, precipitating the need for DDR inhibitors [187].”
BackgroundControl of Apoptosis in Treatment and Biology of Pancreatic Cancer
Modi, S., Kir, D., Banerjee, S., & Saluja, A. K. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25284 · Cited by 58
Metadata
- Authors
- Siddik, Z. H.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Siddik, Zahid H
- ORCID
- Siddik, Zahid H
- Venue
- Oncogene
- Published
- 2003-10-20
- Volume
- 22
- Issue
- 47
- Pages
- 7265-7279
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2164277862
- Cited by
- 3,335
- References
- 154
- Citations by year
- 2026: 67 · 2025: 94 · 2024: 127 · 2023: 161 · 2022: 195 · 2021: 216 · 2020: 203 · 2019: 181 · 2018: 184 · 2017: 185 · 2016: 215 · 2015: 193 · 2014: 205 · 2013: 175 · 2012: 165
- FWCI
- 7.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ca077332-03)
- National Cancer Institute (CA-77332, R01CA082361, CA 82361)
- Topics
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- cisplatin, cisplatin resistance, DNA adducts, DNA cross-linking, apoptosis, ATR signaling, p53, p73, MAPK signaling, DNA damage response, drug uptake, drug inactivation, DNA repair, HER2/neu, PI3K/Akt signaling, Bcl-2, caspase activation, signal transduction
- MeSH terms
- Cisplatin, DNA Damage, DNA Repair, Humans, Tumor Suppressor Protein p53, Apoptosis, Drug Resistance, Neoplasm, MAP Kinase Signaling System
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.